A Randomised, Double-blind, Placebo-controlled, Phase 1 First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single- and Multiple-ascending Doses of BEN8744 in Healthy Subjects.
Latest Information Update: 13 May 2025
At a glance
- Drugs BEN-8744 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors BenevolentAI
Most Recent Events
- 16 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2024 Status changed from active, no longer recruiting to completed.
- 25 Mar 2024 According to a BenevolentAI media release, today announces positive safety data from its Phase Ia, first-in-human. It is anticipated that the full results from this study will be presented in a peer-reviewed forum at a later date.